Inspire Investing LLC Raises Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Inspire Investing LLC raised its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 30.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 75,313 shares of the biopharmaceutical company’s stock after buying an additional 17,541 shares during the period. Inspire Investing LLC owned about 0.12% of Sage Therapeutics worth $409,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in shares of Sage Therapeutics during the second quarter worth about $1,178,000. Point72 DIFC Ltd bought a new position in Sage Therapeutics during the 2nd quarter valued at approximately $153,000. Cubist Systematic Strategies LLC raised its position in Sage Therapeutics by 831.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company’s stock valued at $5,312,000 after purchasing an additional 436,566 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Sage Therapeutics by 1,112.0% in the 2nd quarter. Squarepoint Ops LLC now owns 313,407 shares of the biopharmaceutical company’s stock worth $3,404,000 after buying an additional 287,549 shares during the period. Finally, AQR Capital Management LLC bought a new stake in shares of Sage Therapeutics in the 2nd quarter worth approximately $1,008,000. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

Shares of NASDAQ SAGE opened at $7.10 on Friday. The company has a market cap of $434.33 million, a PE ratio of -1.27 and a beta of 0.91. The firm’s 50 day moving average price is $5.83 and its 200-day moving average price is $7.34. Sage Therapeutics, Inc. has a 52-week low of $4.62 and a 52-week high of $27.67.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. During the same period last year, the company posted ($2.81) earnings per share. The business’s revenue was up 337.1% compared to the same quarter last year. On average, analysts forecast that Sage Therapeutics, Inc. will post -6.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SAGE. Scotiabank dropped their price target on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating for the company in a research note on Wednesday, October 30th. Piper Sandler cut their target price on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. HC Wainwright reiterated a “neutral” rating and set a $14.00 price target on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Oppenheimer lowered their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, October 30th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.53.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.